Grant H. Skrepnek, Ph.D., R.Ph.

Associate Professor

Department of Pharmacy: Clinical and Administrative Sciences

Phone (405) 271-6878 x47105

Fax (4050 271-6430

Office CPB 214



Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.

Education & Experience

Ph.D. in Pharmacy Administration

University of Texas at Austin, Austin, TX

Dissertation: Stock market valuation and firm-level determinants of innovative activity in the pharmaceutical industry.


M.S. in Pharmacy Administration

University of Texas at Austin, Austin, TX

Thesis: The effect of merger and acquisition activity on shareholder returns in the pharmaceutical industry.


B.S. in Pharmacy Business Management

University of Texas at Austin, Austin, TX


Publications & Presentations

1 2 3 4 > >>
  • Miller J L, Ernst K, Neely S, Stephens K, Parker P, Skrepnek G H, Johnson P N. Low-dose versus high-dose methadone for the management of neonatal abstinence syndrome. Journal of Opioid Management. In Press
  • Gentry C A, Giancola S, Kurdgelashvili G, Thind S, Skrepnek G H, Williams R J. A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection. IDSA: Open Forum Infect Dis. 2017; 4 : 1-6
  • Skrepnek G H, Mills J L, Lavery L A, Armstrong D A. Health care service and outcomes among an estimated 6.7 million ambulatory care diabetic foot cases in the U.S. Diabetes Care. 2017; 40 : 936-942
  • Skrepnek G H. Health Economics and Outcomes Research in Cancer. Springer. 2017
  • Miller J L, Lepa T M, Ranallo C, Chaaban H, Skrepnek G H, Johnson P N. Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended?. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2017; 18 : e615-e620
  • 1 2 3 4 > >>